Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
SURG-073 A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-based, Protocol-driven Management in Patients Undergoing Elective Major Cancer Surgery III Not Applicable
1VIT14039 IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) III
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
3475-045 A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer III Chemotherapy, Immunotherapy (Monoclonal Antibody) docetaxel; paclitaxel; vinflunine; pembrolizumab
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
J1365 Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor pembrolizumab
ML28897 My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor trastuzumab; erlotinib; pertuzumab; vemurafenib; vismodegib
GU12-160 A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Oncology Group GU12-160 II Chemotherapy, Signal Transduction Inhibitor docetaxel;
10-096 A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors I / II Chemotherapy, Signal Transduction Inhibitor etoposide; vorinostat
C32496/1105 An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2 I / II Signal Transduction Inhibitor
INCB 24360-202 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors (Phase 1) Followed by a Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Advanced NSCLC (Phase 2)(INCB 24360-202 / MK-3475-037 / KEYNOTE-037) I / II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor INCB024360; pembrolizumab
CD-ON-MEDI4736-1108 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors I / II Immunotherapy (Monoclonal Antibody)
14P.524 An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma and Non-Small Cell Lung Cancer I Immunotherapy (Monoclonal Antibody) pembrolizumab
UPCI-10-115 An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors I Chemotherapy, PARP Inhibitor carboplatin; paclitaxel; veliparib
09-051 A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases I Radiation Therapy Not Applicable
C28001 An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma I Signal Transduction Inhibitor
120066 Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor 5-fluoro-2-deoxycytidine; tetrahydrouridine
OER-RT-042 Phase I Study of Pulsed Low Dose Rate Reirradiation Delivered With 3DCRT/IMRT I Radiation Therapy Not Applicable
11-091 PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES I Radiation Therapy Not Applicable
110060 A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction I Signal Transduction Inhibitor belinostat
C28002 A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies I Chemotherapy, Signal Transduction Inhibitor paclitaxel; alisertib; ;
UPCC 08913 A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green I Imaging Procedure Indocyanine Green
UPCC 27914 A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer I Biological Therapy, Chemotherapy, Hormonal Therapy letrozole; midazolam;
PV-10-LC-01 A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Recurrent Hepatocellular Carcinoma I Chemotherapy PV-10
B2151002 A Phase 1B Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (PI3K/MTor Inhibitor) In Combination With Other Anti-Tumor Agents I Chemotherapy, Signal Transduction Inhibitor docetaxel; cisplatin; dacomitinib;
CD-ON-MEDI3617-1043 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617, a Fully Human Monoclonal Antibody Directed Against ANG2, in Adult Subjects With Advanced Solid Tumors I Immunotherapy (Monoclonal Antibody)
IMGN853-0401 A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors I Immunotherapy (Monoclonal Antibody)
UPCC 30914 Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy 0 Complementary and Alternative Therapy Not Applicable
STUDY00000378 The Value of Integrating Visual Arts (VIVA): Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing Not Specified Not Applicable
14D.272 Use of a Brief Mindful Meditation Practice in Adult Cancer Patients Receiving Radiation Therapy Not Specified Not Applicable
NCT01295658 Cancer Experience Registry Not Specified Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood or Tissue Collection Not Applicable
PRO00000367 A Low-Carbohydrate Diet for Advanced or Metastatic Cancer Not Specified Other Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Penn Non-Treatment Trials trials

Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Phase 1: Solid Tumor Trials trials

Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Proton Therapy Trials trials

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.